Table 6 Impact of SARS-Cov-2 positivity on outcomes on group 2
Outcome | SARS-Cov-2 negative N = 81 (94.2) | SARS-Cov-2 positive N = 5 (5.8) | p-value | Crude OR (95% CI), p-value |
|---|---|---|---|---|
Intra-operative complications, n (%) | 0 (0.0) | 1 (20.0) | 0.06 | n.a. |
Post-operative morbidity, n (%) | 19 (24.7) | 0 (0.0) | 0.58 | n.a. |
Dindo-Clavien 0–2, n (%) | 67 (87.0) | 5 (100.0) | 1.0 | n.a. |
Dindo-Clavien 3–4, n (%) | 8 (10.4) | 0 (0.0) | ||
Dindo-Clavien 5, n (%) | 2 (2.6) | 0 (0.0) | ||
Blood transfusions, n (%) | 6 (7.8) | 1 (20.0) | 0.37 | 2.96 (0.28–30.85), p = 0.37 |
30-day mortality, n (%) | 3 (3.9) | 0 (0.0) | 1.0 | n.a. |
ICU admissions, n (%) | 2 (2.6) | 1 (20.0) | 0.17 | 9.37 (0.69–126.56), p = 0.09 |
Declared Delayed access > 48 h, n (%) | 9 (11.8) | 1 (20.0) | 0.49 | 1.29 (0.13–12.48), p = 0.82 |
Post-operative LOS, median (q1–q3) | 4 (2–9) | 9 (8-10) | 0.11 | n.a. |